Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder—outcome measures beyond symptom control and clinical trials
Lancet Psychiatry
Fecha de publicación: June 2019
DOI: https://doi.org/10.1016/S2215-0366(19)30096-3
Autores: Prof Ian C K Wong, PhD., Prof Tobias Banaschewski, MD
Prof Jan Buitelaar, MD., Samuele Cortese, MD., Döpfner Manfred Döpfner, PhD., Prof Emily Simonoff, MD., et al.
Background: Although pharmacological therapies are recommended as a key component in the treatment of attention-deficit hyperactivity disorder, their use continues to prompt intense debate. Despite considerable research efforts, several gaps in the knowledge base and several questions over the quality of evidence exist.
